Reuters logo
WellPoint says hepatitis C drugs Q1 cost was $50 mln
April 30, 2014 / 1:20 PM / 3 years ago

WellPoint says hepatitis C drugs Q1 cost was $50 mln

April 30 (Reuters) - WellPoint Inc said on Wednesday during a conference call that it had spent $50 million on hepatitis C drugs during the first quarter.

That was the total amount the company spent in 2013 on treatments, it said. Gilead Sciences introduced Sovaldi this year, and with its $84,000 price tag and high cure rates, it has been closely watched by insurers tracking expenses.

WellPoint added $100 million in additional hepatitis C drug costs to its 2014 outlook and said it continued to watch its use closely. (Reporting by Caroline Humer; Editing by Lisa Von Ahn)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below